A combinatorial drug screen in PDX-derived primary rhabdomyosarcoma cells identifies the NOXA - BCL-XL/MCL-1 balance as target for re-sensitization to first-line therapy in recurrent tumors.

Manzella G, Moonamale DC, Rommele M, Bode P, Wachtel M, Schafer BW
Neoplasia. 2021 Sep;23(9):929-938. doi: 10.1016/j.neo.2021.07.001. Epub 2021 Jul 27. PubMed Article

Plasmids from Article

No plasmids are currently publicly available from Addgene for this article.